Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for BridgeBio Oncology Therapeutics, Inc (BBOT : NSDQ)

• Company Description    BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3K? malignancies. BridgeBio Oncology Therapeutics, formerly known as Helix Acquisition Corp. II, is based in SOUTH SAN FRANCISCO. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $12.15 Daily Weekly Monthly 20 Day Moving Average: 173,532 shares Shares Outstanding: 79.20 (millions) Market Capitalization: $962.24 (millions) Beta: 0.14 52 Week High: $13.18 52 Week Low: $8.50 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.79% 0.10% 12 Week 14.09% 9.35% Year To Date 15.71% 1.15%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 200 CLARENDON STREET 52ND FLOOR - BOSTON,MA 02116 USA ph: 857-702-0377 fax: - None None

• General Corporate Information    Officers Bihua Chen - Chairperson and Chief Executive Officer Caleb Tripp - Chief Financial Officer John Schmid - Director Mark McKenna - Director Nebojsa Obradovic - Chief Legal Officer Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 107924102 SIC: 6770 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 79.20 Most Recent Split Date: (:1) Beta: 0.14 Market Capitalization: $962.24 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.44 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.21 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - - 03/31/25 - - ROA 09/30/25 - - 06/30/25 - - 03/31/25 - - Current Ratio 09/30/25 - - 06/30/25 - - 03/31/25 - - Quick Ratio 09/30/25 - - 06/30/25 - - 03/31/25 - - Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - - 03/31/25 - - Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Capital 09/30/25 - - 06/30/25 - - 03/31/25 - -

Powered by Zacks Investment Research ©